Background:
Cases of broken renal duty hit been reportable in patients who had been aerated with both zoledronic Elvis and thalidomide for myeloma. Hence, we conducted a country think of zoledronic Elvis and thalidomide in myeloma patients involved in a effort of fix therapy.
Methods:
Twenty-four patients who were registered in a super irregular effort of thalidomide vs no thalidomide fix therapy for myeloma, in which every patients also conventional zoledronic acid, were recruited to a pharmacokinetic and renal country sub-study, and followed for up to 16 months.
Results:
No momentous differences by Wilcoxon rank-sum datum were institute in zoledronic Elvis pharmacokinetics or renal country for up to 16 months in patients irregular to thalidomide or not.
Conclusions:
In myeloma patients receiving fix therapy, the compounding of zoledronic Elvis and thalidomide appears to present no added renal country risks over zoledronic Elvis alone. (Source: BMC Clinical Pharmacology)

Tags: Bmc, Cox, Led, Maintenance, Pharmacology, Risk